Handelsbanken Fonder AB Acquires 3,069 Shares of Charles River Laboratories International, Inc. $CRL

Handelsbanken Fonder AB boosted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 26.6% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,606 shares of the medical research company’s stock after acquiring an additional 3,069 shares during the quarter. Handelsbanken Fonder AB’s holdings in Charles River Laboratories International were worth $2,285,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the business. Neo Ivy Capital Management bought a new stake in shares of Charles River Laboratories International during the second quarter worth $29,000. Rothschild Investment LLC increased its stake in Charles River Laboratories International by 82.4% in the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after buying an additional 84 shares during the period. Atlantic Union Bankshares Corp bought a new stake in Charles River Laboratories International during the 3rd quarter valued at about $31,000. Geneos Wealth Management Inc. boosted its position in Charles River Laboratories International by 98.0% in the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after buying an additional 145 shares during the period. Finally, Allworth Financial LP grew its stake in Charles River Laboratories International by 172.7% in the 2nd quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock worth $45,000 after acquiring an additional 190 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 1.6%

CRL opened at $175.71 on Wednesday. The firm has a market cap of $8.65 billion, a price-to-earnings ratio of -59.36, a PEG ratio of 3.05 and a beta of 1.64. The company has a current ratio of 1.29, a quick ratio of 1.02 and a debt-to-equity ratio of 0.67. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $228.88. The stock has a fifty day moving average price of $196.77 and a 200-day moving average price of $180.59.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, beating analysts’ consensus estimates of $2.33 by $0.06. The company had revenue of $994.23 million for the quarter, compared to the consensus estimate of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The firm’s revenue for the quarter was down .8% compared to the same quarter last year. During the same quarter last year, the company earned $2.66 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. JPMorgan Chase & Co. lifted their price target on shares of Charles River Laboratories International from $165.00 to $190.00 and gave the company a “neutral” rating in a research note on Monday, December 15th. Barclays reduced their price objective on Charles River Laboratories International from $215.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, February 19th. Robert W. Baird set a $193.00 target price on Charles River Laboratories International in a report on Thursday, February 19th. Morgan Stanley set a $185.00 price target on Charles River Laboratories International in a research report on Monday, December 1st. Finally, TD Cowen cut their price target on Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, February 20th. Ten investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $203.57.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.